| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $360.9M | +69.5% |
| SG&A Expense | $77.2M | +34.8% |
| Pre-tax Income | -$412.9M | -59.6% |
| Income Tax | $891K | +57.1% |
| Net Income | -$413.8M | -59.6% |
| EPS (Basic) | -$2.73 | -45.2% |
| EPS (Diluted) | -$2.73 | -45.2% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $714.0M | +12.4% |
| Accounts Receivable | $2.1M | -61.0% |
| Current Assets | $767.7M | +15.3% |
| Total Assets | $776.2M | +16.5% |
| Current Liabilities | $68.8M | +41.5% |
| Total Liabilities | $68.8M | +41.5% |
| Stockholders' Equity | $707.4M | +14.5% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$375.9M | -75.5% |
| Capital Expenditures | $759K | +110.8% |
| Investing Cash Flow | -$759K | -110.8% |
| Financing Cash Flow | $454.5M | -3.8% |
| Free Cash Flow | -$376.6M | -75.5% |